Long-Term Use of Ruxolitinib in an AML Patient with Posttransplant Steroid Refractory GVHD
Ruxolitinib has become a new therapeutic option for steroid refractory graft-versus-host disease (srGVHD), with a substantial remission rate. Its anti-inflammatory properties by blocking interleukin pathways have made it a novel therapeutic approach to inflammatory disease processes, such as GVHD. T...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Case Reports in Oncological Medicine |
| Online Access: | http://dx.doi.org/10.1155/2020/4936846 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832550447142928384 |
|---|---|
| author | Philip T. Sobash Achuta K. Guddati Vamsi Kota |
| author_facet | Philip T. Sobash Achuta K. Guddati Vamsi Kota |
| author_sort | Philip T. Sobash |
| collection | DOAJ |
| description | Ruxolitinib has become a new therapeutic option for steroid refractory graft-versus-host disease (srGVHD), with a substantial remission rate. Its anti-inflammatory properties by blocking interleukin pathways have made it a novel therapeutic approach to inflammatory disease processes, such as GVHD. The long-term use of ruxolitinib has not been explicitly studied outside the context in the treatment of multiple myeloma. With current clinical trials underway for the use of ruxolitinib in srGVHD, there are still no current guidelines or protocols for long-term clinical use. Of the available literature showing ruxolitinib utilization for srGVHD, most cases lead to resolution and eventual discontinuation. We present a case of a 32-year-old male on ruxolitinib with GVHD status postmatched unrelated donor stem cell transplant (MUD SCT) for acute myeloid leukemia (AML) with FLT3 mutation currently on ruxolitinib for 5 years who is not able to tolerate reduction in dosage due to flare-ups. We discuss the clinical implications and nuance of therapy with ruxolitinib with unknown long-term effects and weigh the risks and benefits. |
| format | Article |
| id | doaj-art-c5bbcba8d9d945fcb3de66725250c624 |
| institution | Kabale University |
| issn | 2090-6706 2090-6714 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Oncological Medicine |
| spelling | doaj-art-c5bbcba8d9d945fcb3de66725250c6242025-02-03T06:06:45ZengWileyCase Reports in Oncological Medicine2090-67062090-67142020-01-01202010.1155/2020/49368464936846Long-Term Use of Ruxolitinib in an AML Patient with Posttransplant Steroid Refractory GVHDPhilip T. Sobash0Achuta K. Guddati1Vamsi Kota2Internal Medicine, White River Health System, Batesville, AR, USAMedical Oncology, Augusta University, Augusta, GA, USAMedical Oncology, Augusta University, Augusta, GA, USARuxolitinib has become a new therapeutic option for steroid refractory graft-versus-host disease (srGVHD), with a substantial remission rate. Its anti-inflammatory properties by blocking interleukin pathways have made it a novel therapeutic approach to inflammatory disease processes, such as GVHD. The long-term use of ruxolitinib has not been explicitly studied outside the context in the treatment of multiple myeloma. With current clinical trials underway for the use of ruxolitinib in srGVHD, there are still no current guidelines or protocols for long-term clinical use. Of the available literature showing ruxolitinib utilization for srGVHD, most cases lead to resolution and eventual discontinuation. We present a case of a 32-year-old male on ruxolitinib with GVHD status postmatched unrelated donor stem cell transplant (MUD SCT) for acute myeloid leukemia (AML) with FLT3 mutation currently on ruxolitinib for 5 years who is not able to tolerate reduction in dosage due to flare-ups. We discuss the clinical implications and nuance of therapy with ruxolitinib with unknown long-term effects and weigh the risks and benefits.http://dx.doi.org/10.1155/2020/4936846 |
| spellingShingle | Philip T. Sobash Achuta K. Guddati Vamsi Kota Long-Term Use of Ruxolitinib in an AML Patient with Posttransplant Steroid Refractory GVHD Case Reports in Oncological Medicine |
| title | Long-Term Use of Ruxolitinib in an AML Patient with Posttransplant Steroid Refractory GVHD |
| title_full | Long-Term Use of Ruxolitinib in an AML Patient with Posttransplant Steroid Refractory GVHD |
| title_fullStr | Long-Term Use of Ruxolitinib in an AML Patient with Posttransplant Steroid Refractory GVHD |
| title_full_unstemmed | Long-Term Use of Ruxolitinib in an AML Patient with Posttransplant Steroid Refractory GVHD |
| title_short | Long-Term Use of Ruxolitinib in an AML Patient with Posttransplant Steroid Refractory GVHD |
| title_sort | long term use of ruxolitinib in an aml patient with posttransplant steroid refractory gvhd |
| url | http://dx.doi.org/10.1155/2020/4936846 |
| work_keys_str_mv | AT philiptsobash longtermuseofruxolitinibinanamlpatientwithposttransplantsteroidrefractorygvhd AT achutakguddati longtermuseofruxolitinibinanamlpatientwithposttransplantsteroidrefractorygvhd AT vamsikota longtermuseofruxolitinibinanamlpatientwithposttransplantsteroidrefractorygvhd |